Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Pfizer Parexel SACT INTERNATIONAL Co., LTD. Acronet Bellsystem24 , Inc. Mitsubishi Kagaku Bio-Clinical Laboratories, inc Sato Pharmaceutical |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00219570 |
To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
Condition | Intervention | Phase |
---|---|---|
Acne Vulgaris |
Drug: clindamycin Drug: nadifloxacin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase IV Clinical Study Of Clindamycin Phaosphate Topical Gel In The Treatment Of Acne Vulgaris |
Estimated Enrollment: | 130 |
Study Start Date: | January 2005 |
Estimated Study Completion Date: | June 2005 |
Ages Eligible for Study: | 13 Years to 35 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A6881003 |
Study First Received: | September 13, 2005 |
Last Updated: | July 24, 2006 |
ClinicalTrials.gov Identifier: | NCT00219570 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Anti-Bacterial Agents Exanthema Clindamycin Facial Dermatoses Clindamycin-2-phosphate |
Facies Skin Diseases Sebaceous Gland Diseases Acne Vulgaris |
Anti-Infective Agents Clindamycin Facial Dermatoses Skin Diseases Clindamycin-2-phosphate Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Sebaceous Gland Diseases Acne Vulgaris Pharmacologic Actions Protein Synthesis Inhibitors Anti-Bacterial Agents Acneiform Eruptions Therapeutic Uses |